Author Index to Volumes 21–23

Aberer, E., 21:121
Abreu, C., 22:125
Adolph, A.J., 22:361
Aguiar Nogueira, J., 22:125
Ahlquist, A., 22:163
Alam, A.N., 21:215
Albert, M.J., 21:215, 22:337, 23:155
Aldeen, W.E., 21:77
Aldridge, K.E., 21:153, 22:35, 22:195
Allen, S.D., 21:153, 21:175
Anderson, S.C., 21:85, 21:95
Andrassy, K., 22:85
Aprahamian, C., 22:183
Ardanuy, C., 21:21
Arroyo, V., 22:141
Azad, A.K., 22:337
The Aztreonam Study Group, 22:249

Baker, D.M., 21:61
Ballou, D., 21:15
Balows, A., 22:307
Baltzan, R.B., 22:361
Barchiesi, F., 23:99
Baron, E.J., 21:141, 23:23, 23:35, 23:75
Barrett, M.S., 23:10
Barry, A.L., 21:175
Barton, A.L., 23:119
Bell, J.M., 21:135
Benito, N., 22:339
Bennion, D.W., 21:203
Bergquist, S.O., 22:163
Berk, S.L., 23:141
Bernard, K., 21:101
Beskid, G., 21:33
Bestrom, J.E., 22:275
Bhattacharya, M.K., 22:337, 23:155
Biedenbach, D.J., 21:1, 21:57, 22:315, 23:123
Blondeau, J.M., 22:361
Bonaventura, M., 23:111
Boschman, C.R., 23:1
Boyle, C.A.J., 21:101
Bradley, S.F., 21:27
Breier, F., 21:121
Brown, G., 22:297
Bruch, H.-P., 22:203
Burke, J.P., 22:167

Caballero, O.L., 22:343
Carlquist, J.F., 21:203
Carlson, J.A., 22:239
Carroll, K., 21:77
Carvajal, A., 21:21
Carvalho, J., 22:343
Chamberlain, M.A., 22:239
Chang, S.-C., 21:81, 23:105, 23:115, 23:147
Chapin, K., 23:35
Chen, H.-C., 23:115
Chen, Y.-C., 23:105, 23:147
Chetchotisakd, P., 22:309
Clarridge, J.E., 21:15
Classen, D.C., 22:167
Congdon, D.D., 23:85
Conly, J.M., 21:101, 22:135
Cooper, B., 21:47
Cooper, R.M., 21:61
Cormican, M.G., 21:51, 21:227, 22:43, 22:119, 22:357, 23:157
Cota Koury, M., 22:343
Craft, B., 22:155
Craig, W.A., 22:89
Cuadros, J.A., 21:115
Cuenca, M., 22:339
Cynamon, M.T., 23:111

Dajani, A.S., 22:105
Dalton, H.P., 21:61
Damiani, A., 21:195
Davey, P., 22:225
Dietz, H., 22:5
Doern, G.V., 22:13, 23:15, 23:119
Dressel, D.C., 23:1

Egleton, J.H., 22:301
Emery, D.D., 23:85
Ena, J., 21:115
The *Enterococcus* Study Group, 21:85
Eriksson, L., 22:163
Eriksson, S., 22:163
Erwin, M.E., 21:85, 21:95, 21:105, 22:119
Escribà, J.M., 21:21

Fan, K., 21:195
Fedorko, D.P., 23:85
Ferraro, M.J., 22:297
Flynn, J., 22:357
Franklin, S.M., 23:85
Freeman, C., 21:47
Friedman, H.D., 23:111
Fritzinger, D., 23:111
Fuchs, P.C., 21:153, 21:175
Fujita, J., 23:77
Funke, G., 22:293

Gadea, I., 22:339
Gannon, F., 22:357
García, A., 21:21
Gatson, A.M., 22:325
Gelfand, M.S., 22:35, 22:155
Gerlach, E.H., 21:153
The German Cefotaxime Study Group, 22:203
Gilson, G.J., 21:65
Glen, D.J., 22:231
Glennon, M., 22:357
Gomez-Herrus, P., 21:115
González-Palacios, R., 21:115
Grogan, J., 22:155
Gustafson, D.R., 22:279
Gutierrez, C., 23:141

Hadfield, T.L., 23:111
Hale, D., 21:77
Hall, G.S., 21:187
Harrington, G.D., 21:27
Hartskeerl, R.A., 22:343
Hartstein, A.I., 22:309
Hayden, M.K., 22:349
Hayden, R.T., 23:1
Heelan, J.S., 22:321
Heyes, B., 21:69
Hogue, S.S., 21:215
Hollis, R.J., 21:9, 21:191, 23:99
Hsieh, W.-C., 21:81, 23:105, 23:147
Hu, B.-S., 22:285
Hurley, J.C., 22:331

Jacobs, J.A., 22:267
Jamieson, F., 21:69
Jenkins, S.G., 23:53
Johnson, C.C., 21:169
Johnson, D.M., 21:209, 23:123
Johnson, W., 21:69
Joho, K.L., 21:55
Jonas, V., 22:297
Jones, R.N., 21:1, 21:51, 21:57, 21:85, 21:95, 21:105, 21:111, 21:153, 21:181, 21:209, 21:227, 22:19, 22:43, 22:119, 22:243, 22:307, 22:315, 22:353, 23:10, 23:123, 23:157
Jorgensen, J.H., 21:175

Kakizoe, T., 23:129
Kaplan, R.L., 21:223
Kappel, J.E., 22:361
Kauffman, C.A., 21:27, 23:135
Kawanishi, K., 23:77
Kearns, G.L., 22:97
Keller, C., 22:159
Kendrew, J., 22:307
Khan, A.M., 22:337, 23:155
Kibriya, A.K.M.G., 21:215
Klade, H., 21:121
Klarlund, M., 21:219
Kujath, P., 22:203

Lamarche, D., 22:321
Lambert, J.R., 21:135
Lamy, Y., 23:111
Lau, Y.-J., 22:285
Lawrence, E., 22:307
Lecour, H., 22:125
Lee, C.K.K., 22:231
Lee, J., 22:239
LeMonte, A.M., 22:309
Letourneau, C., 22:321
Levison, M.E., 21:169
Lin, Y.-H., 22:285
Liu, P.Y.-F., 22:285
Liu, X., 21:129
Lloyd, J.F., 22:167
Lode, H., 22:1
Lonnbro, N., 22:163
Lu, D.C.-T., 23:115
Luger, A., 21:121
Luh, K.-T., 21:81, 23:105, 23:147

Mackenzie, A., 21:69
Marshall, S.A., 21:51, 21:153, 22:249, 22:353, 23:123, 23:157

Martín, R., 21:21
Martínez-Lacasa, J.T., 21:21
Marx, C.E., 21:195
Matushek, M.G., 22:349
May, P., 21:169
Mazens-Sullivan, M., 21:47
McIver, C.J., 22:261
McLaughlin, J.C., 21:65
Mehaffey, P.C., 23:10
Meijer, C.J.L.M., 23:161
Meisler, D.M., 21:187
Messer, S.A., 21:9, 23:99
Midolo, P.D., 21:135
Miller, D., 21:187
Miller, G.H., 22:331
Miller, L.A., 21:223
Miyawaki, H., 23:77
Morris, A.J., 21:195
Mortensen, J.E., 22:301
Mosely, G.H., 21:223
Mota Miranda, A., 22:125
Murray, B.E., 21:119

Nakazawa, T., 23:77
Navasa, M., 22:141
Negayama, K., 23:77
Neto, E.D., 22:343
Nicolau, D.P., 22:49, 22:189
Nightingale, C.H., 21:47, 22:49, 22:189
Nims, L.J., 21:65
Nindl, I., 23:161
Ni Riain, U., 22:357
Niubò, J., 21:21
Nix, D.E., 22:71
Noda, T., 23:129
Norrish, B., 21:69
Novak, C.C., 23:1

Odio, C.M., 22:111
Ohkura, H., 23:129
Oliveira, M.A.A., 22:343
Ostergaard, B.E., 22:77
Ostroff, R.M., 22:253
Otido, J., 23:89
Ouchi, K., 23:77

Parsons, L.M., 23:89
Patel, K.B., 22:49, 22:189
Pereda, J.M., 22:339
Pérez. J.L., 21:21
Pestotnik, S.L., 22:167
Peterson, L.R., 23:1
Pfaller, M.A., 21:9, 21:191, 23:99
Phelps, C.L., 22:309
Pitre, M., 22:135
Pitsakis, P.G., 21:169
Platt, M.W., 21:65
Poupard, J.A., 21:223
Pratt-Rippin, K., 21:187
Prosser, B.LaT., 21:33
Putnam, S.D., 23:10
Pylypchuk, G.B., 22:361

Quintiliani, R., 21:47, 22:49, 22:189

Raddatz, J.K., 22:77
Ramirez, J.A., 22:219
Ramsey, M.A., 21:27
Rawlings, R.D., 22:235
Reagan, D.R., 21:191
Reed, W.E., Jr., 22:209
Reisner, B.S., 22:325
Rhodes, C., 21:61
Rimola, A., 22:141
Rinaldi, M.G., 23:99
Rittenhouse, S.F., 21:223
Roark, M.K., 22:209
Robinson, A., 21:47
Robinson, A.J., 21:77
Romanha, A.J., 22:343
Romanyk, J., 21:115
Rones, R.N., 21:141
Rosenblatt, J.E., 22:275, 22:279
Rosner, H., 22:293
Rotschafer, J.C., 22:77
Roussel, T.J., 21:187
Runehagen, A., 22:163
Runyon, B.A., 21:105

Sader, H.S., 21:85, 21:105, 22:315
Saito, D., 23:129
Salazar, S.A., 23:141
Salvà, J., 21:21
Salyer, J.L., 21:15
Sarker, S.A., 22:337
Satishchandran, V., 21:111
Scalise, G., 23:99
Schein, M., 22:183
Schentag, J.J., 22:71
Schmidt, B.L., 21:121
Schneider, A., 23:161
Schouten, H.C., 22:267
Schwartz, M., 21:169
Scott, D.R., 23:17
Sekiya, T., 23:129
Sewell, D.L., 21:175
Shah, P.M., 22:171
Shapiro, T., 21:111
Shawar, R.M., 21:15
Shayegani, M., 23:89
Shi, Z.-Y., 22:285
Shimosato, Y., 23:129
Shur, A.L., 21:169
Shyr, J.-M., 22:285
Simmons, B.P., 22:155
Simpson, A.J.G., 22:343
Skov, R.L., 21:219
Slavoski, L., 21:169
Sloan, L.M., 22:275
Smith, A.L., 22:331
Smith, T., 22:357
Soeters, P.B., 22:267
Soliman, H., 21:55
Soriano, F., 22:339
Spiegel, J.E., 23:135
Staneck, J.L., 23:61
Steaffens, J.W., 22:253
Stille, W., 22:171
Stobberingh, E.E., 22:267
Stockenhuber, C., 21:121
Stratton, C.W., 22:35
Styrud, J., 22:163
Sugano, K., 23:129
Sugar, A.M., 21:129
Suh, B., 21:111
Sutton, L.D., 21:1, 21:181, 22:353

Takahara, J. 23:77
Takigawa, K., 23:77
Tapsall, J.W., 22:261
Tenover, F., 21:175
Thomson Martin, W., 21:101
Thomson, R.B., Jr., 23:45
Thorsen, S., 21:219
Tiballi, R.N., 23:135
Tin, L.Y., 22:135
Tokue, Y., 23:129
Tomayko, J.F., Jr., 21:119
Trenholme, G.M., 22:349
Truant, A.L., 21:111
Tsai, W.-S., 22:285
Tseng, C.-Y., 22:285
Tucker, L.J., 23:1
Turnidge, J., 21:135, 22:57

Walboomers, J.M.M., 23:161
Waring, A.L., 23:89
Washington, J.A., 21:187
Weinstein, M.P., 21:55, 21:195
Welch, K., 22:297
Wellhoner, M.F., 21:65
Wenzel, R.P., 21:191
Weymouth, L.A., 21:61
Wiedemann, B., 22:5
Wilke, W.W., 21:181
Williams, K.E., 21:101
Wilson, M.L., 21:195
Wilson, W.R., 22:129
Wittmann, D.H., 21:183, 22:173
Woods, G.L., 22:325
Wright, L.J., 21:203

Yamagishi, Y., 23:77
Yamaji, Y., 23:77
Yaschuk, Y., 22:361
Yen, Y., 21:1
Young, L.S., 22:147
Young, R.A., 22:97

Zahm, D.-M., 23:161
Zarins, L.T., 21:27, 23:135

Subject Index to Volumes 21–23

Abcess fluid, *Coccidioides immitis* in, 21:15–19
Abdominal lymphadenopathy, in Whipple's disease, 23:111–113
Accuprobe MAC test, for differentiation of *Mycobacterium xenopi*, 21:195–202
Acidimetric test
  nitrocefin in, 21:353–355
  S1 in, 21:353–355
Acinetobacter baumannii
  amikacin against, 23:105–110
  aztreonam against, 23:105–110
  β-lactamase inhibitors against, 21:111–114
  β-lactams against, 285–291
  cefepime against, 22:285–291
  cefoperazone against, 23:105–110
  cefotaxime against, 22:285–291, 23:105–110
  ceftazidime against, 22:285–291, 23:105–110
  ceftriaxone against, 22:285–291, 23:105–10
  ciprofloxacin against, 22:285–291, 23:105–110
  gentamicin against, 23:105–110
  imipenem against, 22:285–291, 23:105–110
  meropenem against, 22:285–291
  minocycline against, 23:105–110
  norfloxacin against, 23:105–110
  ofloxacin against, 23:105–110
  piperacillin against, 22:285–291, 23:105–110
  ticarcillin against, 23:105–110
  tobramycin against, 23:105–110
Acinetobacter haemolyticus, β-lactamase inhibitors against, 21:111–114
Acinetobacter spp.
  amikacin against, 21:111–114
  β-lactams against, 21:111–114
  cefotaxime against, 21:111–114, 22:71–76
  ceftazidime against, 21:111–114
  ceftriaxone against, 21:111–114
  ciprofloxacin against, 21:33–45
  clavulanate against, 21:111–114
  fleroxacin against, 21:33–45
  imipenem against, 21:111–114
  lomefloxacin against, 21:33–45
  ofloxacin against, 21:33–45
  piperacillin against, 21:111–114
  sulbactam against, 21:111–114
  tazobactam against, 21:111–114
Acquired immunodeficiency syndrome (AIDS)
  Cryptococcus neoformans in, 23:99–103
  disseminated toxoplasmosis in, 22:339–341
Acrodermatitis chronica atrophicans, in Lyme borreliosis, 21:121–128
Actinobacillus actinomycetemcomitans, cefotaxime against, 22:43–48
Aerocarditis urinae, fatal endocarditis due to, 21:219–221
Africa, chancroid in, 23:89–98
Agar culture
  Escherichia coli growth on,261–266
  for GI carriage of vancomycin-resistant enterococci, 23:119–122
  for group B *Streptococcus*, 22:253–259
  for intestinal strongyloidiasis, 23:141–145
Agar dilution method
  for *Acinetobacter baumannii*, 23:105–110
  Etest and, 22:279–284
  for *Helicobacter pylori*, 21:135–140
AIDS. *See* Acquired immunodeficiency syndrome
Alamar blue reagent, in assessing *Saccharomyces cerevisiae*, 23:135–140
Alcaligenes xylosoxidans, cefotaxime against, 22:43–48
AM-1091. *See* Clinafloxacin
AM-833. *See* Fleroxacin
Amebiasis, *Entamoeba histolytica* in, 22:275–278
AMEs. *See* Aminoglycoside-modifying enzymes
Amikacin
  against *Acinetobacter baumannii*, 23:105–110
  against *Acinetobacter* spp., 21:111–114
  against *Pseudomonas aeruginosa*, 22:331–336
Aminoglycoside–modifying enzymes (AMEs), absence of in amikacin-resistant *Pseudomonas aeruginosa* isolates, 22:331–336
Aminoglycosides
  against *Enterococcus faecalis*, 21:85–93
  against *Enterococcus faecium*, 21:85–93
  against neonatal sepsis and meningitis, 22:111–117
  against nosocomial pneumonia, 22:159–161
Amphotericin B
  against *Candida parapsilopsis*, 21:9–14
  against *Cryptococcus neoformans*, 23:99–103
  against *Saccharomyces cerevisiae*, 23:135–140
Ampicillin
  against *Enterococcus faecalis*, 21:85–93
  against *Enterococcus faecium*, 21:85–93
  against neonatal sepsis and meningitis, 22:111–117
  against staphylococci, 21:153–168
Ampicillin–sulbactam
  against Gram-positive bacteria, 21:141–151
  against *Haemophilus influenzae*, 21:141–151
  against staphylococci, 21:153–168
Animal infection models, for cephalosporins, 22:89–96
AP–PCR. *See* Arbitrarily primed polymerase chain reaction
API 20S, for enterococci, 21:85–93, 22:315–319
Arbitrarily primed polymerase chain reaction (AP–PCR), for *Pseudomonas cepacia*, 23:77–83
Area under the inhibitory serum concentration time-curve (AUIC), cefotaxime, 22:71–76
Arteflene (Ro 42-1611), against *Neisseria gonorrhoeae*, 23:11–13
Arthralgias, migratory, in Lyme borreliosis, 21:121–128
Arylsulfatase, in *Mycobacterium xenopi* evaluation, 21:195–202
AUIC. *see* Area under the inhibitory serum concentration time-curve
Azithromycin
  against *Bacteroides fragilis*, 23:147–154
  against enterococci, 23:147–154
  against *Neisseria gonorrhoeae*, 23:11–13
  against peptostreptococci, 23:147–154
  against staphylococci, 23:147–154
  against *Staphylococcus aureus*, 23:147–154
  against *Streptococcus pneumoniae*, 23:147–154
  against *Streptococcus pyogenes*, 23:147–154
Aztreonam
  against *Acinetobacter baumannii*, 23:105–110
  interpretive errors using automated system for susceptibility testing of, 21:57–69
  serious interpretive error among three commercial systems for susceptibility testing of, 22:249–251

Bacillus cereus, cefotaxime against, 22:43–48
BacT/Alert, *Coccidioides immitis* in, 21:15–19
Bactec NR660, *Coccidioides immitis* in, 21:15–19
BACTEC 6A and 16A aerobic resin-containing media, for recovery of microorganisms causing peritonitis, 22:361–368
BACTEC TB method, radiometric, for *Mycobacterium tuberculosis*, 22:325–329
Bacteroides fragilis group
  cefotaxime against, 22:71–76
  erythromycin against, 23:147–154
  Etest and, 22:279–284
  roxithromycin against, 23:147–154
  S1 in detection of, 21:1–8
Baermann technique, for diagnosis of intestinal strongyloidiasis, 23:141–145
β-lactamase
  Enterococcus faecalis and, 21:119
  Haemophilus influenze and, 21:223–225
  S1 chromogenic cephalosporin for detection of, 21:1–8, 21:353–355
β-lactamase inhibitors
  against *Acinetobacter* spp., 21:111–114
  comparative antimicrobial activity of, 21:153–168
  effect of on oxacillin against methicillin-resistant *Staphylococcus aureus*, 21:81–84
  national survey of in vitro spectrum of, 21:141–151
β-lactams

against *Acinetobacter baumannii*, 22:285–291
against *Acinetobacter* spp., 21:111–114
against *Enterobacter* spp., 22:285–291
against *Pseudomonas aeruginosa*, 22:285–291
against *Stenotrophomonas maltophilia*, 22:285–291
Bile esculin azide, for detecting GI carriage of vancomycin-resistant enterococci, 23:119–122
Biofilms, *Candida parapsilopsis* in, 21:9–14
Biosoft 1C3, CMV antigenemia-positive samples in, 21:21–25
Blind subculture, *Coccidioides immitis* in, 21:15–19
Blood agar, subculturing for group B *Streptococcus*, 21:65–68
Blood culture
Acinetobacter baumannii in, 23:105–110
Aerocarditis urinae in, 21:219–221
Candida albicans in, 21:191–194
Candida parapsilopsis in, 21:9–14
Coccidioides immitis in, 21:15–19
cytomegalovirus in, 21:21–25
enterococci in, 21:85–93
Neisseria meningitidis in, 21:115–117
Rahnella aquatilis in, 22:293–296
Saccharomyces cerevisiae in, 23:135–140
for sepsis detection, 23:1–9
viridans streptococci in, 22:267–273
Bone infections, cefotaxime for, 22:105–110
Borrelia burgdorferi, PCR detection of DNA in urine and breast milk of patients with Lyme borelliosis, 21:121–128
Brain heart infusion agar, *Escherichia coli* growth on, 261–266
Breast milk, *Borrelia burgdorferi* PCR in, 21:121–128
Bronchoalveolar lavage fluid, in disseminated toxoplasmosis diagnosis in AIDS patients, 22:339–341
Bronchoscopic study, polymicrobial bacterial pericarditis and, 23:115–118
Broth macrodilution testing
antifungal susceptibility testing with, 21:129–133
of *Cryptococcus neoformans*, 23:99–103
of *Haemophilus influenzae*, 21:175–179
in microtiter assay, 21:129–133
of *Saccharomyces cerevisiae*, 23:135–140
standard, 21:129–133
Broth microdilution testing
of β-lactamase inhibitors against *Acinetobacter* spp., 21:111–114
of enterococci, 21:85–93, 21:95–100
RP 59500 and, 21:169–173
Brucella blood agar, Etest and, 22:279–284
BssHII, in assessing *Candida parapsilopsis* strain variation, 21:9–14

Canadian tertiary care institution, twice-daily dosing of cefotaxime in, 22:135–140
Candida parapsilopsis
against amphotericin B, 21:9–14
against fluconazole, 21:9–14
against 5-fluorocytosine, 21:9–14
against itraconazole, 21:9–14
strain variation in, 21:9–14
Capnocytophaga spp., cefotaxime against, 22:43–48
Carryover contamination, in PCR technique, 21:181–185
Cataract extraction, extracapsular, *Propionibacterium acnes* in, 21:187–190
Catheter-related blood stream infections, *Candida parapsilopsis* in, 21:9–14
Cefazolin, against *Propionibacterium acnes*, 21:187–190
Cefepime
against *Acinetobacter baumannii*, 22:285–291
against *Enterobacter* spp., 22:285–291
against *Pseudomonas aeruginosa*, 22:285–291
against staphylococci, 21:153–168
against *Stenotrophomonas maltophilia*, 22:285–291
Cefoperazone, against *Acinetobacter baumannii*, 23:105–110
Cefotaxime
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:111–114, 22:71–76
against *Actinobacillus actinomycetemcomitans*, 22:43–48
against *Alcaligenes xylosoxidans*, 22:43–48
against *Bacteroides fragilis* group, 22:71–76
against *Capnocytophaga* spp., 22:43–48
against *Clostridium perfringens*, 22:173–182
cost effectiveness in pediatrics, 22:231–233
desacetylcefotaxime and, 22:19–33, 22:49–55, 22:57–69, 22:77–83
econotherapeutics and, 22:209–217
against *Eikenella corrodens*, 22:43–48
against *Enterobacter cloacae*, 22:71–76
against *Enterobacteriaceae*, 22:57–69
against *Enterobacter* spp., 22:285–291
against *Enterococcus* spp., 22:71–76
against *Erysipelothrix rhusiopathiae*, 22:43–48
against *Escherichia coli*, 22:173–182
against *Fusobacterium nucleatum*, 22:43–48
against Gram-negative pneumonia, 22:13–17
against *Haemophilus influenzae*, 22:105–110
against *Haemophilus* spp., 22:147–154, 22:173–182
against *Klebsiella* spp., 22:173–182
against *Neisseria* spp., 22:57–69
against neonatal sepsis and meningitis, 22:111–117
in the 1990's, 22:1–3
non-ICU pathogens and, 22:13–17
against nosocomial pneumonia, 22:159–161, 22:171–172
ofloxacin and, 22:71–76
once daily vs. ceftriaxone twice daily, 22:155–157
against *Pasteurella multocida*, 22:43–48
against pediatric infections, 22:105–110
against pediatric meningitis, 22:125–127
against *Peptostreptococcus* spp., 22:173–182
pharmacokinetics of
in dialysis patients, 22:85–87
in healthy volunteers and patients, 22:49–55
in moderately severe infections, 22:49–55
twice-daily dosage, 22:71–76
against *Plesiomonas shigelloides*, 22:43–48
against pneumococci, 22:19–33, 22:173–182
against postoperative pneumonia, 22:203–207
against *Proteus mirabilis*, 22:173–182
against *Providencia* spp., 22:173–182
against *Pseudomonas aeruginosa*, 22:19–33, 22:71–76, 22:285–291
against *Serratia marcescens*, 22:71–76
against severe intra-abdominal infection, 22:183–188
against spontaneous bacterial peritonitis, 21:105–110
against spontaneous bacterial peritonitis with cirrhosis, 22:141–145
against staphylococci, 22:19–33, 22:173–182
against *Staphylococcus aureus*, 22:71–76, 22:147–154, 22:173–182, 22:195–201
against *Staphylococcus epidermidis*, 22:195–201
against *Staphylococcus saprophyticus*, 22:195–201
against *Stenotrophomonas maltophilia*, 22:285–291
against *Streptococcus pneumoniae*, 22:35–42
against *Streptococcus* spp., 22:19–33
against streptococci
hemolytic, 22:147–154
pyogenic, 22:173–182
viridans group, 22:173–182
against surgical infection, 22:173–182
summation, 22:243–247
therapeutic exchange of for ceftriaxone, 22:235–237
therapeutic options for, 22:77–83
twice daily, 22:159–161, 22:163–166, 22:167–169, 22:203–207
unchanged antibacterial activity over years, 22:5–12
Cefotaxime (CTX)
desacetylcefotaxime and, 22:97–104
dosing schedules for in selected institutions, 22:147–154
economics of BID, 22:135–140
against Gram-negative bacilli, 22:125–127
against *Haemophilus influenzae*, 22:125–127
against *Neisseria meningitidis*, 22:125–127
against *Staphylococcus* spp., 22:125–127
against *Streptococcus pneumoniae*, 22:119–123, 22:125–127
Cefotaxime–desacetylcefotaxime (DES-CTX), against spontaneous bacterial peritonitis, 21:105–110
Cefpirome, against spontaneous bacterial peritonitis, 21:105–110
Ceftazidime
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:111–114
against *Citrobacter freundii*, 21:141–151

against *Enterobacteriaceae*, 21:141–151
against *Enterobacter* spp. 21:141–151, 22: 285–291
against *Pseudomonas aeruginosa*, 22:285–291
against *Stenotrophomonas maltophilia*, 22: 285–291
Ceftizoxime, against *Streptococcus pneumoniae*, 22:35–42
Ceftriaxone
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:111–114
cost effectiveness in pediatrics, 22:231–233
econotherapeutics and, 22:209–217
against *Enterobacter* spp., 22:285–291
Etest and, 22:279–284
against nosocomial pneumonia, 22:171–172
against *Pseudomonas aeruginosa*, 22:285–291
against *Stenotrophomonas maltophilia*, 22: 285–291
against *Streptococcus pneumoniae*, 22:35–42
therapeutic exchange of cefoxatime for, 22:235–237
twice daily vs. cefotaxime once daily, 22: 155–157
Cell culture, of bronchoalveolar lavage fluid for diagnosis of toxoplasmosis in AIDS, 22:339–341
Cell ghosts, amikacin-resistant *Pseudomonas aeruginosa* isolates and, 22:331–336
Cephalosporins
against *Enterobacteriaceae*, 21:153–168, 22: 89–96, 22:129–134
formulary selections of, 22:129–134
against *Haemophilus influenzae*, 22:129–134
interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum, 22:89–96
metronidazole with, for intra-abdominal infections, 22:189–194
against neonatal sepsis and meningitis, 22:111–117
against pneumococci, 22:105–110
against spontaneous bacterial peritonitis, 21:105–110
against staphylococci, 22:89–96
against *Staphylococcus aureus*, 22:89–96
against streptococci, 22:89–96
Cerebrospinal fluid (CSF)
Neisseria meningitidis in, 21:115–117
Streptococcus pneumoniae in, 22:119–123, 22:35–42
CFUs. *See* Colony forming units
Chancroid, *Haemophilus ducreyi* in, 23:89–98
Children
cefoxatime for meningitis in, 22:125–127
Moraxella septicemia in, 21:215–217
septicemia due to *Vibrio cholerae* 0139 Bengal in, 22:337–338
Chloramphenicol
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Chloroquine, against *Neisseria gonorrhoeae*, 23:11–13
Chronic wastage, in Whipple's disease, 23: 111–113
CI-960. *See* Clinafloxacin
Ciprofloxacin
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:33–45
in disk diffusion testing, 21:209–213, 21: 227–230
DU-6859a and, 21:51–54
against *Enterobacter* spp., 22:285–291
against enterococci, 23:123–127
against *Enterococcus faecalis*, 21:27–31, 21: 85–93
against *Enterococcus faecium*, 21:85–93
against *Providencia* spp., 21:33–45
against *Pseudomonas aeruginosa*, 22:285–291
against *Pseudomonas* spp., 21:33–45
against *Rahnella aquatilis*, 22:293–296
against spontaneous bacterial peritonitis, 21:105–110
against *Staphylococcus aureus*, 21:27–31, 21: 33–45
against *Staphylococcus epidermidis*, 21:33–45
against *Staphylococcus saprophyticus*, 21: 33–45, 21:227–230
against *Stenotrophomonas maltophilia*, 22: 285–291
against *Xanthomonas* spp., 21:33–45
Cirrhosis, with spontaneous bacterial peritonitis, 22:141–145
Citrobacter freundii
ceftazidime against, 21:141–151
piperacillin–tazobactam against, 21:141–151
Clarithromycin
against *Bacteroides fragilis*, 23:147–154
against enterococci, 23:147–154
against peptostreptococci, 23:147–154
against staphylococci, 23:147–154
against *Staphylococcus aureus*, 23:147–154
against *Streptococcus pneumoniae*, 23:147–154
against *Streptococcus pyogenes*, 23:147–154
Clavulanate, against *Acinetobacter* spp., 21: 111–114
Clavulanic acid, against *Staphylococcus aureus*, 21:81–84
CLED agar, *Escherichia coli* growth on,261–266
CLIA 88, impact of on clinical microbiological laboratory, 23:35–43
Clinafloxacin (CI-960, AM-1091, PD127371)
DU-6859a and, 21:51–54
against *Enterococcus faecalis*, 21:27–31, 21: 85–93
against *Enterococcus faecium*, 21:85–93
modified criteria for disk diffusion tests, 21:209–213
against *Staphylococcus aureus*, 21:27–31
Clindamycin
Etest and, 22:279–284
against *Neisseria gonorrhoeae*, 23:11–13
Clinical microbiology laboratory director, changing role of, 23:45–51
Clonab C10/C11, CMV antigenemia-positive samples in, 21:21–25
Clostridium perfringens, cefotaxime against, 22:173–182
Clostridium spp., Etest and, 22:279–284
CMV. *See* Cytomegalovirus
Coagulase positivity, exfoliative toxin A-producing *Staphylococcus aureus* and, 21:69–75
Coccidioides immitis, in BacT/Alert, 21:15–19
Colony forming units (CFUs), group A *Streptococcus*, 21:61–64
Colony morphology, in *Mycobacterium xenopi* evaluation, 21:195–202
Colorimetric disk assays
nitrocefin in, 21:353–355
S1 in, 21:353–355
for *Saccharomyces cerevisiae*, 23:135–140
Community-acquired pneumonia, switch therapy in, 22:219–223
Contamination, in PCR technique, 21:181–185
Conventional culture, for group A *Streptococcus*, 21:61–64
Corynebacteria, and one day vs. two day incubation of urine cultures, 21:55–56
Cryptococcus neoformans
amphotericin B against, 23:99–103
D0870 against, 23:99–103
DNA typing of, 23:99–103
fluconazole against, 23:99–103
flucytosine against, 23:99–103
itraconazole against, 23:99–103
triazoles against, 23:99–103
CSF. *See* Cerebrospinal fluid
CTX. *See* Cefotaxime
Cutaneous infections, *Enterococcus* spp. in, 21:141–151
Cysteine, *Escherichia coli* requirement for, 22: 261–266
Cystic fibrosis, *Pseudomonas aeruginosa* in, 22:331–336
Cytomegalovirus (CMV)
antigenemia assay, monoclonal antibodies for, 21:21–25
specimen-dependent variability in culture, 21:203–207

D0870, against *Cryptococcus neoformans*, 23: 99–103
Dalfopristin. *See* RP 59500
dCTX. *See* Desacetylcefotaxime
Dermatologic disorders, in Lyme borreliosis, 21:121–128
Desacetylcefotaxime (dCTX)
cefotaxime and, 22:19–33, 22:49–55, 22:57–69, 22:77–83, 22:97–104,
against pneumococci, 22:19–33
against *Pseudomonas aeruginosa*, 22:19–33
against staphylococci, 22:19–33
against *Streptococcus pneumoniae*, 22:119–123
against *Streptococcus* spp., 22:19–33
DES–CTX. *See* Cefotaxime–desacetylcefotaxime
Dexamethasone, for neonatal sepsis and meningitis, 22:111–117
DFA. *See* Direct fluorescent antibody

Dialysis patients
cefotaxime in, 22:85–87
peritonitis in, 22:361–368
Diarrhea
childhood, with *Moraxella* septicemia, 21:215–217
neonatal, *Vibrio cholerae* 0139 Bengal as cause of, 23:155–156
Difco automated ESP system, for sepsis detection, 23:1–9
Difco Thiol broth bottle, for sepsis detection, 23:1–9
Direct fluorescent antibody (DFA) stain, for *Giardia lamblia*, 21:77–79
Direct latex agglutination method, for group B *Streptococcus*, 21:65–68
Dirithromycin
against *Bacteroides fragilis*, 23:147–154
against enterococci, 23:147–154
against peptostreptococci, 23:147–154
against staphylococci, 23:147–154
against *Staphylococcus aureus*, 23:147–154
against *Streptococcus pneumoniae*, 23:147–154
against *Streptococcus pyogenes*, 23:147–154
Disk diffusion susceptibility testing
ciprofloxacin in, 21:209–213, 21:227–230
clinafloxacin in, 21:209–213
DU-6859a in, 23:123–127
DV-7751a in, 23:123–127
of enterococci, 21:85–93, 21:95–100
fleroxacin in, 21:209–213
of fluoroquinolone-resistant isolates, 21:227–230
fluoroquinolones in, 21:209–213
of *Haemophilus influenzae*, 21:175–179
of *Helicobacter pylori*, 21:135–140
lomefloxacin in, 21:227–230
nitrocefin in, 21:1–8
norfloxacin in, 21:227–230
S1 in, 21:1–8
SCH 27899 in, 23:157–160
DNA fingerprinting, of *Pseudomonas cepacia*, 23:77–83
DNA typing
of *Candida parapsilopsis*, 21:9–14
of *Cryptococcus neoformans*, 23:99–103
Doxycycline
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
against *Neisseria gonorrhoeae*, 23:11–13
DU-6859a
cross-resistance analysis for, 21:51–54
against glycopeptide-resistant enterococci, 23:123–127
DV-7751a, against glycopeptide-resistant enterococci, 23:123–127

Econotherapeutics, 22:209–217
EIA. *See* Enzyme immunoassay
87/312. *See* Nitrocefin
Eikenella corrodens, cefotaxime against, 22:43–48
EK. *See* Electrophoretic karyotyping
Electrophoretic karyotyping (EK)
of *Candida parapsilopsis*, 21:9–14
of *Cryptococcus neoformans*, 23:99–103
ELISA. *See* Enzyme-linked immunosorbent assay
Endocarditis, fatal, *Aerocarditis urinae* in, 21:219–221
Endophthalmitis, chronic, *Propionibacterium acnes* in, 21:187–190
Endotracheal intubation, pericarditis after, 23:115–118
Entamoeba histolytica, ELISA for, 22:275–278
Enterobacter cloacae
cefotaxime against, 22:71–76
pulsed-field gel electrophoresis and, 22:309–314
in spontaneous bacterial peritonitis, 21:105–110
Enterobacteriaceae
cefotaxime against, 22:57–69
ceftazidime against, 21:141–151
cephalosporins against, 21:153–168, 22:89–96, 22:129–134
imipenem against, 21:153–168
piperacillin–tazobactam against, 21:141–151, 21:153–168
S1 in detection of, 21:1–8
Enterobacterial repetitive intergenic consensus sequence PCR, of exfoliative toxin A-producing *Staphylococcus aureus*, 21:69–75
Enterobacter spp.
β-lactams against, 22:285–291
cefepime against, 22:285–291
cefotaxime against, 22:285–291
ceftazidime against, 21:141–151, 22:285–291
ceftriaxone against, 22:285–291
ciprofloxacin against, 22:285–291
imipenem against, 22:285–291
meropenem against, 22:285–291
piperacillin against, 22:285–291
piperacillin–tazobactam against, 21:141–151
Enterococci
azithromycin against, 23:147–154
cefotaxime against, 22:19–33
clarithromycin against, 23:147–154
desacetylcefotaxime against, 22:19–33
dirithromycin against, 23:147–154
emerging multiply-resistant, 21:85–93, 21:95–100
erythromycin against, 23:147–154
fluoroquinolone-resistant, 21:27–31
gentamicin-resistant, 21:27–31
glycopeptide-resistant
DU-6859a against, 23:123–127
DV-7751a against, 23:123–127
novobiocin against, 21:47–50
ramoplanin against, 21:47–50
RP 59500 against, 21:47–50
streptogramin against, 21:47–50
vancomycin against, 21:47–50
glycopeptides against, 21:95–100
roxithromycin against, 23:147–154
teicoplanin against, 21:95–100
vancomycin against, 21:95–100
vancomycin-resistant
DU-6859a against, 23:123–127
DV-7751a against, 23:123–127
gastrointestinal carriage of, 23:119–122
levofloxacin against, 22:349–352
SCH 27899 against, 23:157–160
vancomycin-susceptible, levofloxacin against, 22:349–352
Enterococcus faecalis
aminoglycosides against, 21:85–93
ampicillin against, 21:85–93
API 20S for species identification, 22:315–319
β-lactamase tests for screening, 21:119
chloramphenicol against, 21:85–93
ciprofloxacin against, 21:27–31, 21:85–93
clinafloxacin against, 21:27–31, 21:85–93
doxycycline against, 21:85–93
erythromycin against, 21:85–93
fluoroquinolones against, 21:85–93
gentamicin against, 21:85–93
glycopeptides against, 21:85–93
kanamycin against, 21:85–93
novobiocin against, 21:85–93
penicillin against, 21:85–93
pulsed-field gel electrophoresis and, 22:309–314
RP 59500 against, 21:169–173
sparfloxacin against, 21:85–93
spectinomycin against, 21:85–93
streptomycin against, 21:85–93
teicoplanin against, 21:85–93
tetracyclines against, 21:85–93
trimethoprim/sulfamethoxazole against, 21:85–93
trospectomycin against, 21:85–93
vancomycin against, 21:85–93, 21:169–173
Vitek System for species identification, 22:315–319
Enterococcus faecium
aminoglycosides against, 21:85–93
ampicillin against, 21:85–93
API 20S for species identification, 22:315–319
chloramphenicol against, 21:85–93
ciprofloxacin against, 21:85–93
clinafloxacin against, 21:85–93
doxycycline against, 21:85–93
erythromycin against, 21:85–93
fluoroquinolones against, 21:85–93
gentamicin against, 21:85–93
glycopeptides against, 21:85–93
kanamycin against, 21:85–93
novobiocin against, 21:85–93
penicillin against, 21:85–93
sparfloxacin against, 21:85–93
spectinomycin against, 21:85–93
streptomycin against, 21:85–93
teicoplanin against, 21:85–93
tetracyclines against, 21:85–93
trimethoprim/sulfamethoxazole against, 21:85–93
trospectomycin against, 21:85–93
vancomycin against, 21:85–93
Vitek System for species identification, 22:315–319
Enterococcus raffinosus
API 20S for species identification, 22:315–319
Vitek System for species identification, 22:315–319
Enterococcus spp.

API 20S for species idendification, 22:315–319
cefotaxime against, 22:71–76
nitrocefin and, 21:353–355
piperacillin–tazobactam against, 21:141–151
S1 and, 21:353–355
Vitek System for species idendification, 22:315–319
Enzyme immunoassay (EIA)
for group B *Streptococcus*, 22:321–324
for *Mycoplasma pneumoniae*, 23:85–88
Enzyme-linked immunosorbent assay (ELISA)
for *Entamoeba histolytica*, 22:275–278
for *Giardia lamblia*, 21:77–79
for *Mycoplasma pneumoniae*, 23:85–88
Enzyme-producing species, S1 in detection of, 21:1–8
Enzymes, for *Borrelia burgdorferi* DNA detection, 21:121–128
Eosinophilia, in strongyloidiasis, 23:141–145
Error-rate bounding methods
ciprofloxacin and, 21:227–230
for *Helicobacter pylori*, 21:135–140
lomefloxacin and, 21:227–230
norfloxacin and, 21:227–230
Erysipelothrix rhusiopathiae, cefotaxime against, 22:43–48
Erythema migrans, in Lyme borreliosis, 21:121–128
Erythromycin
against *Bacteroides fragilis*, 23:147–154
against enterococci, 23:147–154
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
against peptostreptococci, 23:147–154
staphylococcal resistance to, 21:69–75
against staphylococci, 23:147–154
against *Staphylococcus aureus*, 23:147–154
against *Streptococcus pneumoniae*, 23:147–154
against *Streptococcus pyogenes*, 23:147–154
against *Vibrio cholerae* 0139 Bengal, 23:155–156
Escherichia coli
amoxicillin against, 22:301–306
amoxicillin–clavanulate against, 22:301–306
cefaclor against, 22:301–306
cefixime against, 22:301–306
cefotaxime against, 22:173–182
cefpodoxime against, 22:301–306
cefuroxime against, 22:301–306
clarithromycin against, 22:301–306
furopenem against, 22:301–306
in neonatal sepsis and meningitis, 22:111–117
piperacillin–tazobactam against, 21:141–151
pulsed-field gel electrophoresis and, 22:309–314
in spontaneous bacterial peritonitis, 21:105–110
Etest
for anaerobic bacteria, 22:279–284
for enterococci, 21:85–93, 21:95–100
for *Helicobacter pylori*, 21:135–140
for penicillin susceptibility testing of *Neisseria meningitidis*, 21:115–117
Europe, cefotaxime dosage in, 22:147–154
Everninomicins, disk diffusion testing of, 23:157–160
Exfoliative toxin A, *Staphylococcus aureus*, 21:69–75
Extracorporeal membrane oxygenation, *Saccharomyces cerevisiae* and, 23:135–140
Extraintestinal infection, *Vibrio cholerae* 0139 Bengal in, 22:337–338

Fansidar. *See* Sulfadoxine–pyrimethamine
Fecal specimens, *Giardia lamblia* in, 21:77–79
Feminine hygiene products, effect of on group B *Streptococcus* detection, 22:253–259
Flavobacterium spp., cefotaxime against, 22:43–48
Fleroxacin (Ro 23-6240, AM-833)
against *Acinetobacter* spp., 21:33–45
DU-6859a and, 21:51–54
modified criteria for disk diffusion tests, 21:209–213
against *Providencia* spp., 21:33–45
against *Pseudomonas* spp., 21:33–45
against *Staphylococcus aureus*, 21:33–45
against *Staphylococcus epidermidis*, 21:33–45
against *Staphylococcus saprophyticus*, 21:33–45
against *Xanthomonas* spp., 21:33–45
Fluconazole
against *Candida parapsilopsis*, 21:9–14
against *Cryptococcus neoformans*, 23:99–103
against *Saccharomyces cerevisiae*, 23:135–140
Flucytosine
against *Cryptococcus neoformans*, 23:99–103
against *Saccharomyces cerevisiae*, 23:135–140
5-Fluorocytosine, against *Candida parapsilopsis*, 21:9–14
Fluoroquinolone-resistant isolates, in disk diffusion susceptibility testing, 21:227–230
Fluoroquinolones
enterococcal resistance to, 21:27–31
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
against glycopeptide-resistant enterococci, 23:123–127
against *Haemophilus influenzae*, 21:175–179
in vitro activities of, 21:33–45
modified criteria for disk diffusion tests, 21:209–213
against spontaneous bacterial peritonitis, 21:105–110
Formalin-ethyl acetate concentration method, for diagnosis of intestinal strongyloidiasis, 23:141–145
Formazan dye, in microtiter assay, 21:129–133
Fungi
NCCLS standard broth macrodilution assay for, 21:129–133
sepsis and, 23:1–9
Fusobacterium nucleatum, cefotaxime against, 22:43–48

Gastrointestinal (GI) tract
group B *Streptococcus* in, 21:65–68
Shigella boydii in, 22:337–338
vancomycin-resistant enterococci in, 23:119–122
Genital ulcer disease, *Haemophilus ducreyi* in, 23:89–98
Genomic tests, of exfoliative toxin A-producing *Staphylococcus aureus*, 21:69–75
Genotypic diversity, of *Candida parapsilopsis*, 21:9–14
Gen-Probe direct test, for *Mycobacterium tuberculosis*, 22:297–299
Gentamicin
against *Acinetobacter baumannii*, 23:105–110
enterococcal resistance to, 21:27–31
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
against staphylococci, 21:169–173
Germany, cefotaxime dosage in, 22:147–154
GI tract. *See* Gastrointestinal tract
Giardia lamblia, ELISA assays for, 21:77–79
Glucose, *Candida parapsilopsis* in, 21:9–14
β-D-Glucuronidase, among *Escherichia coli* and Enterobacteriaceae causing urinary tract infections, 22:261–266
Glycopeptides
enterococcal resistance to, 21:47–50, 21:95–100, 23:123–127
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Gram-negative spp.
cefotaxime against, 22:57–69, 22:125–127, 22:159–161
fluoroquinolones against, 21:33–45
in HIV, 22:293–296
in intensive care units, 22:285–291
piperacillin–tazobactam against, 21:141–151, 21:153–168
Gram-positive spp.
Aerococcus spp. and, 21:219–221
ampicillin–sulbactam against, 21:141–151
cefotaxime against unusual, 22:43–48
fluoroquinolones against, 21:33–45
furopenem against, 22:301–306
imipenem against, 21:141–151
nitrocefin and, 21:353–355
piperacillin–tazobactam against, 21:141–151
SCH 27899 against, 23:157–160
S1 and, 21:1–8, 21:353–355
Gram stain, of *Coccidioides immitis*, 21:15–19
Grepafloxacin (OPC 17116), against *Haemophilus influenzae*, 21:175–179
*gro*El gene, *Haemophilus ducreyi*, 23:89–98
Gynecologic infections, *Enterococcus* spp. in, 21:141–151

Haemophilus influenzae
amoxicillin against, 22:301–306
amoxicillin–clavanulate against, 22:301–306

ampicillin–sulbactam against, 21:141–151
β-lactamase producing, 21:223–225
cefaclor against, 22:301–306
cefixime against, 22:301–306
cefotaxime against, 22:105–110, 22:125–127
cefpodoxime against, 22:301–306
cefuroxime against, 22:301–306
cephalosporins against, 22:129–134
clarithromycin against, 22:301–306
fluroquinolones against, 21:175–179
furopenem against, 22:301–306
grepafloxacin against, 21:175–179
imipenem against, 21:141–151
PF 131628 against, 21:175–179
piperacillin–tazobactam against, 21:141–151, 21:153–168
S1 in detection of, 21:1–8
Haemophilus spp., cefotaxime against, 22:147–154, 22:173–182
Health care reform in the 1990's, and clinical microbiology laboratory, 23:15–16, 23:75–76
Health maintenance organizations (HMOs), clinical microbiology in, 23:17–21
Helicobacter pylori, metronidazole against, 21:135–140
High-grade squamous intraepithelial lesions, human papillomavirus detection in, 23:161–163
HIV. *See* Human immunodeficiency virus
HMOs. *See* Health maintenance organizations
Hospital formularies
cephalosporin selection for, 22:129–134
MART for formulary replacement, 22:239–242
HPV. *See* Human papillomavirus
Human immunodeficiency virus (HIV)
Legionella pneumophila serogroup Lansing 3 in, 21:101–103
Mycobacterium xenopi in, 21:195–202
Rahnella aquatilis in, 22:293–296
Human papillomavirus (HPV), in high-grade squamous intraepithelial lesions, 23:161–163
Hybrid capture assay, for human papillomavirus detection, 23:161–163
Hypersensitivity pneumonitis, *Legionella pneumophila* serogroup Lansing 3 in, 21:101–103

ICU. *See* Intensive care unit
IFA. *See* Immunofluorescent antibody assay
IgG/IgM antibody test system, for *Mycoplasma pneumoniae*, 23:85–88
IHA. *See*Indirect hemagglutination test
Imipenem
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:111–114
against *Enterobacteriaceae, 21:153–168*
against *Enterobacter* spp., 22:285–291
against Gram-positive bacteria, 21:141–151
against *Haemophilus influenzae*, 21:141–151
interpretive errors using automated system for susceptibility testing of, 21:57–69
against *Pseudomonas aeruginosa*, 22:285–291
against staphylococci, 21:153–168
against *Stenotrophomonas maltophilia*, 22:285–291
Immunocompromised individuals, cytomegalovirus in, 21:203–207
Immunofluorescent antibody assay (IFA), for *Mycoplasma pneumoniae*, 23:85–88
Immunosuppressive agents, *Legionella pneumophila* serogroup Lansing 3 and, 21:101–103
Indirect hemagglutination test (IHA), for *Entamoeba histolytica*, 22:275–278
Infants, pharmacokinetics of cefotaxime and desacetylcefotaxime in, 22:97–104
Intensive care unit (ICU)
cefotaxime use outside of, 22:13–17
Gram-negative bacilli resistance and, 22:285–291
neonatal, *Candida albicans* as nosocomial pathogen in, 21:191–194
Intra-abdominal infections
cefotaxime against, 22:183–188
cephalosporin–metronidazole combinations for, 22:189–194
Enterococcus spp. in, 21:141–151
metronidazole against, 22:183–188
Intrapartum carriage, of group B *Streptococcus*, 21:65–68
Intravenous drug abuser, *Rahnella aquatilis* bacteremia in HIV-infected, 22:293–296
Intravenous rehydration therapy, for *Vibrio cholerae* 0139 Bengal-induced diarrhea, 23:155–156
Itraconazole
against *Candida parapsilopsis*, 21:9–14
against *Cryptococcus neoformans*, 23:99–103
against *Saccharomyces cerevisiae*, 23:135–140

Joint infections, cefotaxime for, 22:105–110

Kanamycin
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Kirby–Bauer disk diffusion method, modified, for *Helicobacter pylori*, 21:135–140
Klebsiella oxytoca, β-D-glucuronidase activity in, 22:261–266
Klebsiella pneumoniae
amoxicillin against, 22:301–306
amoxicillin–clavanulate against, 22:301–306
cefaclor against, 22:301–306
cefixime against, 22:301–306
cefpodoxime against, 22:301–306
cefuroxime against, 22:301–306
clarithromycin against, 22:301–306
furopenem against, 22:301–306
pulsed-field gel electrophoresis and, 22:309–314
in spontaneous bacterial peritonitis, 21:105–110
Klebsiella spp., cefotaxime against, 22:173–182

Lactation, in Lyme borreliosis, 21:121–128
Larva, strongyloides, 23:141–145
Legionella pneumophila serogroup Lansing 3, pneumonia with pleural effusion due to, 21:101–103
Leptospira interrogans, differential diagnosis of, 22:343–348
Levofloxacin
DU-6859a and, 21:51–54
against glycopeptide-resistant enterococci, 23:123–127
LIM-selective broth medium, group B, *Streptococcus* enrichment in, 22:321–324
Listeria monocytogenes
cefotaxime against, 22:43–48
in neonatal sepsis and meningitis, 22:111–117
Lomefloxacin
against *Acinetobacter* spp., 21:33–45
in disk diffusion susceptibility testing, 21:227–230
against *Providencia* spp., 21:33–45
against *Pseudomonas* spp., 21:33–45
against *Staphylococcus aureus*, 21:33–45
against *Staphylococcus epidermidis*, 21:33–45
against *Staphylococcus saprophyticus* 21:33–45, 21:227–230
against *Xanthomonas* spp., 21:33–45
Lower respiratory tract infections, *Pseudomonas aeruginosa* in, 21:141–151
Lyme borreliosis, PCR detection of *Borrelia burdorferi* in, 21:121–128

MAC. *See Mycobacterium avium* complex
MacConkey agar
Escherichia coli growth on, 261–266
without crystal violet, in *Mycobacterium xenopi* evaluation, 21:195–202
Macrobroth dilution method, for *Propionibacterium acnes*, 21:187–190
Macrodilution assay, antifungal testing with, 21:129–133
Macrolides
against *Neisseria gonorrhoeae*, 23:11–13
resistance to in Taiwanese bacteria, 223:147–154
Macrorestriction digest profiles, of *Candida parapsilopsis*, 21:9–14
Malaria, antigonococcal activity of drugs used against, 23:11–13
MART. *See* Multidisciplinary antibiotic review team
MBCs. *See* Minimum bactericidal concentrations
McFarland standard, Etest and, 22:279–284
Mediastinitis, polymicrobial bacterial pericarditis with, 23:115–118
Mefloquine, against *Neisseria gonorrhoeae*, 23:11–13

Membrane enzyme-linked immunoassay, for *Mycoplasma pneumoniae*, 23:85–88
Meningitis
  cefotaxime for, 22:105–110, 22:111–117, 22:125–127
  Streptococcus pneumoniae in, 22:35–42
Meropenem
  against *Acinetobacter baumannii*, 22:285–291
  against *Enterobacter* spp., 22:285–291
  against *Pseudomonas aeruginosa*, 22:285–291
  against *Stenotrophomonas maltophilia*, 22:285–291
Methicillin, staphylococcal resistance to 21:27–31, 21:81–84, 22:301–306, 23:157–160
Metronidazole
  against anaerobic isolates, 21:153–168
  against *Helicobacter pylori*, 21:135–140
  against intra-abdominal infections, 22:183–188, 22:189–194
Mg^{2+}, AP-PCR and, 23:77–83
MGIT mycobacteria growth indicator tubes, for *Mycobacterium tuberculosis*, 22:325–329
Microtiter-based assay, antifungal testing with, 21:129–133
Middlebrook broth, in *Mycobacterium xenopi* evaluation, 21:195–202
Minimum bactericidal concentrations (MBCs)
  amphotericin B, 21:131
  cefazolin, 21:187–190
  fluconazole, 21:131
  grepafloxacin, 21:175–179
  ketoconazole, 21:131
  novobiocin, 21:47–50
  PD 131628, 21:175–179
  penicillin, 21:187–190
  ramoplanin, 21:47–50
  RP 59500, 21:47–50
  streptogramin, 21:47–50
  vancomycin, 21:187–190
  XTT assay and, 21:129–133
Minimum inhibitory concentrations (MICs)
  amikacin, 21:111–114, 22:331–336, 23:105–110
  amoxicillin, 22:301–306
  amoxicillin–clavulanate, 22:301–306
  amphotericin B, 21:9–14, 23:135–140
  arteflene, 23:11–13
  azithromycin, 23:11–13, 23:147–154
  aztreonam, 23:105–110
  β-lactam, 21:111–114, 22:285–291
  β-lactamase inhibitor, 21:111–114
  cefaclor, 22:301–306
  cefazolin, 21:187–190
  cefepime, 22:285–291
  cefixime, 22:301–306
  cefoperazone, 23:105–110
  cefotaxime, 21:105–110, 21:111–114, 22:13–17, 22:19–33, 22:35–42, 22:43–48, 22:57–69, 22:71–76, 22:77–83, 22:89–96, 23:105–110, 22:119–123, 22:173–182, 22:195–201, 22:285–291
  cefotaxime–desacetylcefotaxime, 21:105–110
  cefpirome, 21:105–110
  cefpodoxime, 22:301–306
  ceftazidime, 21:111–114, 22:119–123, 22:285–291, 23:105–110
  ceftizoxime, 22:35–42
  ceftriaxone, 21:111–114, 22:35–42, 22:119–123, 22:285–291, 23:105–110
  cefuroxime, 22:301–306
  cephalosporin, 21:105–110, 22:89–96
  chloramphenicol, 22:119–123
  chloroquine, 23:11–13
  ciprofloxacin, 21:27–31, 21:33–45, 21:51–54, 21:105–110, 21:227–230, 22:285–291, 23:105–110, 23:123–127
  clarithromycin, 22:301–306, 23:147–154
  clavulanate, 21:111–114
  clavulanic acid, 21:81–84
  clinafloxacin, 21:27–31, 21:51–54
  clindamycin, 23:11–13
  desacetylcefotaxime, 22:19–33, 22:119–123
  dirithromycin, 23:147–154
  doxycycline, 23:11–13
  DU-6859a, 21:51–54, 23:123–127
  DV-7751a, 23:123–127
  erythromycin, 23:147–154
  fleroxacin, 21:33–45, 21:51–54
  fluconazole, 21:9–14, 23:135–140
  flucytosine, 23:135–140
  5-fluorocytosine, 21:9–14
  fluoroquinolone, 21:105–110
  furopenem, 22:301–306
  gentamicin, 23:105–110
  imipenem, 21:111–114, 22:285–291, 23:105–110
  itraconazole, 21:9–14, 23:135–140
  levofloxacin, 21:51–54, 23:123–127
  lomefloxacin, 21:33–45, 21:227–230
  macrolide, 23:11–13
  mefloquine, 23:11–13
  meropenem, 22:285–291
  minocycline, 23:105–110
  norfloxacin, 21:227–230, 23:105–110
  novobiocin, 21:47–50
  ofloxacin, 21:33–45, 21:51–54, 21:105–110, 23:105–110, 23:123–127
  oxacillin, 21:81–84
  penicillin, 21:115–117, 21:187–190
  piperacillin, 21:111–114, 22:285–291, 23:105–110
  primaquine, 23:11–13
  pyrimethamine, 23:11–13
  quinacrine, 23:11–13
  quinine, 23:11–13
  ramoplanin, 21:47–50
  rifampin, 22:119–123
  roxithromycin, 23:147–154
  RP 59500, 21:47–50
  sparfloxacin, 21:51–54
  streptogramin, 21:47–50
  sulbactam, 21:81–84, 21:111–114
  sulfadoxine–pyrimethamine, 23:11–13
  tazobactam, 21:81–84, 21:111–114
  teicoplanin, 21:95–100
  ticarcillin, 23:105–110
  tobramycin, 23:105–110
  vancomycin, 21:47–50, 21:95–100, 21:187–190, 22:119–123
Minocycline, against *Acinetobacter baumannii*, 23:105–110
Molecular biology, encyclopedia of, 22:307
Molecular typing, of *Candida parapsilopsis*, 21:9–14
Monoclonal antibodies, for cytomegalovirus antigenemia assay, 21:21–25
Monofluo kit CMV, CMV antigenemia-positive samples in, 21:21–25
Moraxella catarrhalis
  amoxicillin against, 22:301–306
  amoxicillin–clavanulate against, 22:301–306
  cefaclor against, 22:301–306
  cefixime against, 22:301–306
  cefpodoxime against, 22:301–306
  cefuroxime against, 22:301–306
  clarithromycin against, 22:301–306
  furopenem against, 22:301–306
  piperacillin–tazobactam against, 21:153–168
  S1 in detection of, 21:1–8
Moraxella spp., in septicemia in children with diarrheal disease, 21:215–217
Molds, NCCLS standard broth macrodilution assay for, 21:129–133
Multidisciplinary antibiotic review team (MART), for hospital formulary replacement, 22:239–242
Myalgias, migratory, in Lyme borreliosis, 21:121–128
Mycobacteria, non-RI SSCP in identification of, 23:129–133
Mycobacterium avium complex (MAC), differentiation of from *Mycobacterium xenopi*, 21:195–202
Mycobacterium tuberculosis
  Gen-Probe direct test for, 22:297–299
  growth indicator tubes for, 22:325–329
  isoniazid against, 22:325–329
  PCR for, 22:357–360
  rifampin against, 22:325–329
Mycobacterium xenopi, differentiation of from *Mycobacterium avium* complex, 21:195–202
Mycoplasma pneumoniae, rapid enzyme immunoassay system for serologic diagnosis of, 23:85–88

Nasopharyngeal carcinoma, polymicrobial bacterial pericarditis and, 23:115–118
Neck abcess fluid, *Coccidioides immitis* in, 21:15–19
Neisseria gonorrhoeae
  arteflene against, 23:11–13
  azithromycin against, 23:11–13
  chloroquine against, 23:11–13
  clindamycin against, 23:11–13
  doxycycline against, 23:11–13
  macrolides against, 23:11–13
  mefloquine against, 23:11–13
  piperacillin–tazobactam against, 21:153–168
  primaquine against, 23:11–13
  pyrimethamine against, 23:11–13
  quinacrine against, 23:11–13
  quinine against, 23:11–13
  S1 in detection of, 21:1–8

sulfadoxine–pyrimethamine against, 23:11–13
Neisseria meningitidis
cefoxatime against, 22:125–127
penicillin against, 21:115–117
Neisseria spp., cefotaxime against, 22:57–69
Neonatal intensive care unit, *Candida albicans* as nosocomial pathogen in, 21:191–194
Neonates
exfoliative toxin A-producing *Staphylococcus aureus* in, 21:69–75
group B *Streptococcus* infections in, 21:65–68
meningitis in, 22:111–117
sepsis in, 22:111–117
Vibrio cholerae 0139 Bengal causes diarrhea in, 23:155–156
Neoplasm, Whipple's disease mimicking malignant, 23:111–113
New technology, evaluation of in clinical microbiology laboratory, 23:53–60
p-Nitro-α-acetylamino-β-hydroxypropiophenone, in *Mycobacterium xenopi* evaluation, 21:195–202
Nitrocefin (87/312), for β-lactamase detection, 21:1–8, 21:353–355
Nondenaturing silver-stained polyacrylamide gel analysis, of PCR products for differential diagnosis of *Leptospira interrogans*, 22:343–348
Nonradioisotopic single-strand conformation polymorphism analysis, mycobacteria identified via, 23:129–133
Norfloxacin
against *Acinetobacter baumannii*, 23:105–110
in disk diffusion susceptibility testing, 21:227–230
against *Staphylococcus saprophyticus*, 21:227–230
Nosocomial pathogen
Candida albicans as, 21:191–194
Candida parapsilopsis as, 21:9–14
Enterococcus spp. as, 21:141–151
Pseudomonas cepacia as, 23:77–83
Nosocomial pneumonia
aminoglycosides against, 22:159–161
cefotaxime against, 22:159–161, 22:171–172
ceftriaxone against, 22:171–172
No-target false-positives, in PCR technique, 21:181–185
Novobiocin
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
against glycopeptide-resistant enterococci, 21:47–50

Obstetric outpatients, group B *Streptococcus* infections in, 21:65–68
Ofloxacin
against *Acinetobacter baumannii*, 23:105–110
against *Acinetobacter* spp., 21:33–45
cefotaxime and, 22:71–76
DU-6859a and, 21:51–54
against glycopeptide-resistant enterococci, 23:123–127
against *Providencia* spp., 21:33–45
against *Pseudomonas* spp., 21:33–45
against spontaneous bacterial peritonitis, 21:105–110
against *Staphylococcus aureus*, 21:33–45
against *Staphylococcus epidermidis*, 21:33–45
against *Staphylococcus saprophyticus*, 21:33–45
against *Xanthomonas* spp., 21:33–45
OIA. *See* Optical immunoassay
OPC 17116. *See Grepafloxacin*
Operation Desert Storm, Whipple's disease and, 23:111–113
Optical immunoassay (OIA)
for group A *Streptococcus*, 21:61–64
for group B *Streptococcus*, 22:253–259
Ova & Parasite concentration, for *Giardia lamblia*, 21:77–79
Oxacillin, against Staphylococcus aureus, 21:81–84

Packaged culture media, for sepsis detection, 23:1–9
Parallel and blind study, to assess anti-pp65 monoclonal antibodies for CMV antigenemia assay, 21:21–25
Pasteurella multocida, cefotaxime against, 22;43–48
Plesiomonas shigelloides, cefotaxime against, 22:43–48
PCR. *See* Polymerase chain rection
PD 131628, against *Haemophilus influenzae*, 21:175–179
PD127371. *See* Clinafloxacin
Pediatric infections, cefotaxime for, 22:105–110
Pediatric meningitis, cefoxatime for, 22:125–127
Penicillin
against *Bacteroides fragilis*, 21:169–173
against *Neisseria meningitidis*, 21:115–117
against pneumococci, 22:105–110
against *Propionibacterium acnes*, 21:187–190
streptococcal resistance to, 22:119–123
against *Streptococcus pneumoniae*, 22:35–42, 22:301–306
Peptostreptococci
azithromycin against, 23:147–154
cefotaxime against, 22:173–182
clarithromycin against, 23:147–154
dirithromycin against, 23:147–154
erythromycin against, 23:147–154
roxithromycin against, 23:147–154
Perforated bowel, *Saccharomyces cerevisiae* in, 23:135–140
Pericarditis, after endotracheal intubation, 23:115–118
Peritonitis
BACTEC media for microorganisms in, 22:361–368
Saccharomyces cerevisiae in, 23:135–140
Persian Gulf veterans, Whipple's disease and, 23:111–113
PFGE. *See* Pulsed-field gel electrophoresis
pH, AP–PCR and, 23:77–83
Phage typing, of exfoliative toxin A-producing *Staphylococcus aureus*, 21:69–75
Pharmacoeconomics, antimicrobial, 22:225–229
Pharyngitis, group A *Streptococcus*, 21:61–64
Phenotypic typing, of *Pseudomonas cepacia*, 23:77–83
Pigmentation in response to light, in *Mycobacterium xenopi* evaluation, 21:195–202
Piperacillin
against *Acinetobacter baumannii*, 22:285–291, 23:105–110
against *Acinetobacter* spp., 21:111–114
against *Enterobacteriaceae*, 21:141–151, 21:153–168
against *Enterobacter* spp., 22:285–291
against *Pseudomonas aeruginosa*, 22:285–291
against staphylococci, 21:153–168
against *Stenotrophomonas maltophilia*, 22:285–291
Piperacillin–tazobactam
against *Bacteroides fragilis*, 21:153–168
against *Citrobacter freundii*, 21:141–151
against *Enterobacter* spp. 21:141–151
against *Enterococcus* spp., 21:141–151
against *Escherichia coli*, 21:141–151
against Gram-negative bacilli, 21:141–151, 21:153–168
against Gram-positive cocci, 21:141–151
against *Haemophilus influenzae*, 21:141–151, 21:153–168
against *Moraxella catarrhalis*, 21:153–168
national survey of in vitro spectrum of, 21:141–151
against *Neisseria gonorrhoeae*, 21:153–168
against *Pseudomonas aeruginosa*, 21:141–151
against staphylococci, 21:153–168
Plasmodium spp., antigonococcal activity of drugs used against, 23:11–13
Pleural effusion, in pneumonia, 21:101–103
Pneumococcal meningitis, *Streptococcus pneumoniae* in, 22:35–42
Pneumococci
cefotaxime against, 22:19–33, 22:173–182
cephalosporins against, 22:105–110
desacetylcefotaxime against, 22:19–33
penicillin against, 22:105–110
Pneumonia
aminoglycosides against, 22:159–161
cefotaxime against, 22:13–17, 22:159–161, 22:203–207
with pleural effusion, *Legionella pneumophila* serogroup Lansing 3 in, 21:101–103
switch therapy in, 22:219–223
Polymerase chain reaction (PCR)
automation of, 21:181–185
for *Borrelia burgdorferi*, 21:121–128
for exfoliative toxin A-producing *Staphylococcus aureus*, 21:69–75
for *Haemophilus ducreyi groEl* gene, 23:89–98
for human papillomavirus, 23:161–163
for *Leptospira interrogans*, 22:343–348

for mycobacteria, 23:129–133
for *Mycobacterium tuberculosis*, 22:357–360
Polymicrobial bacterial pericarditis, with mediastinitis, after endotracheal intubation, 23:115–118
Portugal, cefotaxime for pediatric meningitis in, 22:125–127
Postoperative pneumonia, cefotaxime for, 22:203–207
pp65 antigen, for cytomegalovirus antigenemia assay, 21:21–25
Pregnancy, group B *Streptococcus* in, 21:65–68, 22:321–324
Prevotella spp.
nitrocefin and, 21:353–355
S1 and, 21:353–355
Primaquine, against *Neisseria gonorrhoeae*, 23:11–13
Primers, for *Borrelia burgdorferi* DNA detection, 21:121–128
Propionibacterium acnes
cefazolin against, 21:187–190
penicillin against, 21:187–190
ProspecT/*Giardia* ELISA, for *Giardia lamblia*, 21:77–79
Proteus mirabilis, cefotaxime against, 22:173–182
Providencia spp.
cefotaxime against, 22:173–182
ciprofloxacin against, 21:33–45
in cystic fibrosis, 22:331–336
fleroxacin against, 21:33–45
lomefloxacin against, 21:33–45
ofloxacin against, 21:33–45
Pseudomonas aeruginosa
amikacin against, 22:331–336
β-lactams against, 22:285–291
cefepime against, 22:285–291
cefotaxime against, 22:19–33, 22:71–76, 22:285–291
ceftazidime against, 22:285–291
ceftriaxone against, 22:285–291
ciprofloxacin against, 22:285–291
desacetylcefotaxime against, 22:19–33
imipenem against, 22:285–291
meropenem against, 22:285–291
in neonatal sepsis and meningitis, 22:111–117
piperacillin against, 22:285–291
piperacillin–tazobactam against, 21:141–151
pulsed-field gel electrophoresis and, 22:309–314
Pseudomonas cepacia, arbitrarily primed PCR for, 23:77–83
Pseudomonas spp.
ciprofloxacin against, 21:33–45
fleroxacin against, 21:33–45
lomefloxacin against, 21:33–45
ofloxacin against, 21:33–45
Pulsed-field gel electrophoresis (PFGE)
for *Candida parapsilopsis*, 21:9–14
for exfoliative toxin A-producing *Staphylococcus aureus*, 21:69–75
for *Pseudomonas cepacia*, 23:77–83
sequential bacterial isolate typing by, 22:309–314
Pyelonephritis, cefotaxime against, 22:13–17
Pyrimethamine, against *Neisseria gonorrhoeae*, 23:11–13

Quality management, and clinical microbiology laboratory, 23:23–34
Quinacrine, against *Neisseria gonorrhoeae*, 23:11–13
Quinine, against *Neisseria gonorrhoeae*, 23:11–13
Quinupristin. *See* RP 59500

Rahnella aquatilis
ciprofloxacin against, 22:293–296
in HIV-infected intravenous drug abuser, 22:293–296
Ramoplanin, against glycopeptide-resistant enterococci, 21:47–50
Rapid blood culture systems, *Coccidioides immitis* in, 21:15–19
Rapid chromogenic cephalosporin method, for methicillin-resistant *Staphylococcus aureus*, 21:81–84
RAPID ID 32 Strep system, for bloodstream isolates of viridans streptococci, 22:267–273
Rectal swabs, for group B *Streptococcus*, 21:65–68, 22:321–324
Relative growth rates, in *Mycobacterium xenopi* evaluation, 21:195–202
Remel menbrane EIA, for *Mycoplasma pneumoniae*, 23:85–88
Replicate cultures, cytomegalovirus in, 21:203–207
Respiratory infections
cefoptaxime against, 22:77–83
Pseudomonas cepacia in, 23:77–83
Restriction fragment polymorphism (RFLP), using *Candida albicans*-specific DNA probe, 21:191–194
RFLP. *See* Restriction fragment polymorphism
Rhodococcus equi, cefotaxime against, 22:43–48
Rifampin, against *Streptococcus pneumoniae*, 22:119–123
Ro 23-6240. *See* Fleroxacin
Ro 42-1611. *See* Arteflene
Robotic system, automated PCR performed by, 21:181–185
Roxithromycin
against *Bacteroides fragilis*, 23:147–154
against enterococci, 23:147–154
against peptostreptococci, 23:147–154
against staphylococci, 23:147–154
against *Staphylococcus aureus*, 23:147–154
against *Streptococcus pneumoniae*, 23:147–154
against *Streptococcus pyogenes*, 23:147–154
RP 59500 (quinupristin/dalfopristin)
against *Bacteroides fragilis*, 21:169–173
against *Enterococcus faecalis*, 21:169–173
against glycopeptide-resistant enterococci, 21:47–50
against staphylococci, 21:169–173
RPMI 1640, phenol red deletion from, 21:129–133
rRNA gene fragments, mycobacteria and, 23:129–133

S1 chromogenic cephalosporin, for β-lactamase detection, 21:1–8, 21:353–355
Sabouraud broth, *Candida parapsilopsis* in, 21:9–14
Saccharomyces cerevisiae
amphotericin B against, 23:135–140
fluconazole against, 23:135–140
flucytosine against, 23:135–140
itraconazole against, 23:135–140
Saline, for neonatal sepsis and meningitis, 22:111–117
Salmonella enteritidis
amoxicillin against, 22:301–306
amoxicillin–clavanulate against, 22:301–306
cefaclor against, 22:301–306
cefixime against, 22:301–306
cefpodoxime against, 22:301–306
cefuroxime against, 22:301–306
clarithromycin against, 22:301–306
furopenem against, 22:301–306
SCH 27899, disk diffusion testing of, 23:157–160
Selective media, for detecting GI carriage of vancomycin-resistant enterococci, 23:119–122
Sepsis
cefotaxime for, 22:111–117
optimizing detection of, 23:1–9
Septicemia
Moraxella, in children with diarrheal disease, 21:215–217
due to *Vibrio cholerae* 0139 Bengal, 22:337–338
Serratia marcescens, cefotaxime against, 22:71–76, 22:77–83
Shell vial cultures, replicate, cytomegalovirus in, 21:203–207
Shigella boydii, *Vibrio cholerae* 0139 Bengal and, 22:337–338
Shigella spp.
amoxicillin against, 22:301–306
amoxicillin–clavanulate against, 22:301–306
cefaclor against, 22:301–306
cefixime against, 22:301–306
cefpodoxime against, 22:301–306
cefuroxime against, 22:301–306
clarithromycin against, 22:301–306
furopenem against, 22:301–306
Single-strand DNA bands, mycobacteria and, 23:129–133
Skin infections
cefotaxime against, 22:13–17
Lyme borreliosis in, 21:121–128
Slime production, by *Candida parapsilopsis*, 21:9–14
Soft tissue infections, cefotaxime against, 22:13–17, 22:105–110
Spain, *Neisseria meningitidis* in, 21:115–117
Sparfloxacin
DU-6859a and, 21:51–54
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93

Species-specific primers, from *Haemophilus ducreyi gro* EL, 23:89–98
Specimen-dependent variability, of cytomegalovirus in culture, 21:203–207
Specimen storage, effect of on group B *Streptococcus* detection, 22:253–259
Spectinomycin
  against *Enterococcus faecalis*, 21:85–93
  against *Enterococcus faecium*, 21:85–93
Spherules, *Coccidioides immitis* in, 21:15–19
Spontaneous bacterial peritonitis
  cefotaxime against, 21:105–110, 22:141–145
  cefotaxime–desacetylcefotaxime against, 21:105–110
  cefpirome against, 21:105–110
  cephalosporins against, 21:105–110
  ciprofloxacin against, 21:105–110
  fluoroquinolones against, 21:105–110
  ofloxacin against, 21:105–110
Staged abdominal repair, antimicrobials in, 22:183–188
Staphylococci
  Aerococcus spp. and, 21:219–221
  ampicillin against, 21:153–168
  ampicillin–sulbactam against, 21:153–168
  azithromycin against, 23:147–154
  cefepime against, 21:153–168
  cefotaxime against, 22:19–33, 22:173–182
  cephalosporins against, 22:89–96
  clarithromycin against, 23:147–154
  desacetylcefotaxime against, 22:19–33
  dirithromycin against, 23:147–154
  erythromycin against, 23:147–154
  gentamicin against, 21:169–173
  imipenem against, 21:153–168
  piperacillin against, 21:153–168
  piperacillin–tazobactam against, 21:153–168
  roxithromycin against, 23:147–154
  RP 59500 against, 21:169–173
  SCH 27899 against, 23:157–160
Staphylococcus aureus
  azithromycin against, 23:147–154
  cefotaxime against, 22:71–76, 22:147–154, 22:173–182, 22:195–201
  cephalosporins against, 22:89–96
  ciprofloxacin against, 21:33–45
  clarithromycin against, 23:147–154
  dirithromycin against, 23:147–154
  erythromycin against, 21:69–75, 23:147–154
  exfoliative toxin A-producing, 21:69–75
  fleroxacin against, 21:33–45
  lomefloxacin against, 21:33–45
  methicillin-resistant
    amoxicillin against, 22:301–306
    amoxicillin–clavanulate against, 22:301–306
    cefaclor against, 22:301–306
    cefixime against, 22:301–306
    cefpodoxime against, 22:301–306
    cefuroxime against, 22:301–306
    ciprofloxacin against, 21:27–31
    clarithromycin against, 22:301–306
    clavulanic acid against, 21:81–84
    clinafloxacin against, 21:27–31
    furopenem against, 22:301–306
    oxacillin against, 21:81–84
    sulbactam against, 21:81–84
    tazobactam against, 21:81–84
  in neonatal sepsis and meningitis, 22:111–117
  ofloxacin against, 21:33–45
  pulsed-field gel electrophoresis and, 22:309–314
  roxithromycin against, 23:147–154
  S1 in detection of, 21:1–8
Staphylococcus epidermidis
  cefotaxime against, 22:195–201
  ciprofloxacin against, 21:33–45
  fleroxacin against, 21:33–45
  lomefloxacin against, 21:33–45
  in neonatal sepsis and meningitis, 22:111–117
  nitrocefin and, 21:353–355
  ofloxacin against, 21:33–45
  S1 and, 21:353–355
Staphylococcus saprophyticus
  cefotaxime against, 22:195–201
  ciprofloxacin against, 21:33–45, 21:227–230
  fleroxacin against, 21:33–45
  lomefloxacin against, 21:33–45, 21:227–230
  norfloxacin against, 21:227–230
  ofloxacin against, 21:33–45
Staphylococcus spp., cefoxatime against, 22:125–127
Staphyloslide negativity, exfoliative toxin A-producing *Staphylococcus aureus* and, 21:69–75*Stenotrophomonas maltophilia*
  β-lactams against, 22:285–291
  cefepime against, 22:285–291
  cefotaxime against, 22:43–48, 22:285–291
  ceftazidime against, 22:285–291
  ceftriaxone against, 22:285–291
  ciprofloxacin against, 22:285–291
  imipenem against, 22:285–291
  meropenem against, 22:285–291
  piperacillin against, 22:285–291
Stool specimens, in strongyloidiasis, 23:141–145
Streptococci
  Aerococcus spp. and, 21:219–221
  cephalosporins against, 22:89–96
Streptococci, group A, culture vs. rapid methods for, 21:61–64
Streptococci, group B
  detection of, 22:253–259
  increased recovery of, 21:65–68
  in neonatal sepsis and meningitis, 22:111–117
Streptococci, hemolytic, cefotaxime against, 22:147–154
Streptococci, pyogenic, cefotaxime against, 22:173–182
Streptococci, viridans group
  bloodstream isolates of, 22:267–273
  cefotaxime against, 22:173–182
Streptococcus anginosus, bloodstream isolates of, 22:267–273
Streptococcus constellatus
  bloodstream isolates of, 22:267–273
  LIM-selective broth medium and, 22:321–324
Streptococcus intermedius, bloodstream isolates of, 22:267–273
Streptococcus milleri, bloodstream isolates of, 22:267–273
Streptococcus mitis, bloodstream isolates of, 22:267–273
Streptococcus oralis, bloodstream isolates of, 22:267–273
Streptococcus pneumoniae
  amoxicillin against, 22:301–306
  amoxicillin–clavanulate against, 22:301–306
  azithromycin against, 23:147–154
  cefaclor against, 22:301–306
  cefixime against, 22:301–306
  cefotaxime against, 22:35–42, 22:119–123, 22:125–127
  cefpodoxime against, 22:301–306
  ceftizoxime against, 22:35–42
  ceftriaxone against, 22:35–42
  cefuroxime against, 22:301–306
  clarithromycin against, 22:301–306, 23:147–154
  Difco automated ESP system and, 23:1–9
  dirithromycin against, 23:147–154
  furopenem against, 22:301–306
  penicillin against, 21:169–173, 22:35–42, 22:301–306
  RP 59500 against, 21:169–173
Streptococcus pyogenes
  azithromycin against, 23:147–154
  clarithromycin against, 23:147–154
  dirithromycin against, 23:147–154
  erythromycin against, 23:147–154
  roxithromycin against, 23:147–154
Streptococcus sanguis II, bloodstream isolates of, 22:267–273
Streptococcus spp.
  cefotaxime against, 22:19–33
  desacetylcefotaxime against, 22:19–33
Streptogramins, against glycopeptide-resistant enterococci, 21:47–50
Streptomycin
  against *Enterococcus faecalis*, 21:85–93
  against *Enterococcus faecium*, 21:85–93
Strongyloidiasis, agar plate in detection of, 23:141–145
Subculturing, for group B *Streptococcus*, 21:65–68
Sulbactam
  against *Acinetobacter* spp., 21:111–114
  against *Staphylococcus aureus*, 21:81–84
Sulfadoxine–pyrimethamine (Fansidar), against *Neisseria gonorrhoeae*, 23:11–13
Surgical infections, cefotaxime against, 22:173–182
Sweden, cefotaxime sodium twice daily in, 22:163–166
Switch therapy, in community-acquired pneumonia, 22:219–223
Synergy, desacetylcefotaxime and, 22:19–33

Taiwan, macrolide resistance of bacteria from, 23:147–154
Tamponade, pericardial effusion with, 23:115–118

Tazobactam
against *Acinetobacter* spp., 21:111–114
against *Staphylococcus aureus*, 21:81–84
Team approach, to hospital formulary replacement, 22:239–242
Technology impact on cost, in clinical laboratory, 23:61–73
Teicoplanin
against enterococci, 21:95–100
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Tetracyclines
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Throat swabs, of group A *Streptococcus*, 21:61–64
Thymidine, *Escherichia coli* requirement for, 22:261–266
Ticarcillin, against *Acinetobacter baumannii*, 23:105–110
Ticarcillin–clavulanic acid, against anaerobic isolates, 21:153–168
Time–kill studies, of RP 59500, 21:169–173
Tissue biopsy specimens, cytomegalovirus in, 21:203–207
TMP/SMZ. *See* Trimethoprim sulfamethoxazole
Tobramycin, against *Acinetobacter baumannii*, 23:105–110
Todd-Hewitt broth, group B *Streptococcus* in, 21:65–68
Toxoplasma gondii, in cell cultures from bronchoalveolar lavage fluid, 22:339–341
Transport medium, for group B *Streptococcus*, 22:253–259
Triazoles, against *Cryptococcus neoformans*, 23:99–103
Trimethoprim/sulfamethoxazole (TMP/SMZ)
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Triple therapy, against *Helicobacter pylori*, 21:135–140
Trospectomycin
against *Enterococcus faecalis*, 21:85–93
against *Enterococcus faecium*, 21:85–93
Etest and, 22:279–284
Tube dilution assay, antifungal testing with, 21:129–133
Tuberculosis, Gen-Probe direct test and, 22:297–299

United States
β-lactamase-producing *Haemophilus influenzae* in, 21:223–225
cefotaxime dosage in, 22:105–110, 22:147–154, 22:167–169
emerging multiply-resistant enterococci in, 21:85–93, 21:95–100
Unusual pathogens, cefotaxime against, 22:43–48
Urinary tract infections
cefotaxime against, 22:13–17, 22:77–83, 22:105–110
Enterobacteriaceae in, 22:261–266
Escherichia coli in, 22:261–266
Urine cultures
Borrelia burgdorferi PCR in, 21:121–128
cytomegalovirus in, 21:203–207
one-day vs. two-day incubation of, 21:55–56

Vaginal swabs, for group B *Streptococcus*, 21:65–68, 22:253–259, 22:321–324
Vancomycin
enterococcal resistance to, 22:349–352, 23:119–122, 23:123–127, 23:157–160
against enterococci, 21:47–50, 21:95–100
against *Enterococcus faecium*, 21:85–93
against *Enterococcus faecalis*, 21:85–93, 21:169–173
against *Propionibacterium acnes*, 21:187–190
Very major errors (VMEs), Etest and, 22:279–284
Vibrio cholerae 0139 Bengal
neonatal diarrhea caused by, 23:155–156
septicemia due to, 22:337–338
Vitek System, for enterococcal identification, 22:315–319
VMEs. *See* Very major errors

Wampole Isolater, for sepsis detection, 23:1–9
Whipple's disease, presentation of, 23:111–113
Whole agar, Etest and, 22:279–284

Xanthomonas maltophilia, cefotaxime against, 22:43–48
Xanthomonas spp.
ciprofloxacin against, 21:33–45
fleroxacin against, 21:33–45
lomefloxacin against, 21:33–45
ofloxacin against, 21:33–45
X-colonies, in *Mycobacterium xenopi* evaluation, 21:195–202
XTT, in microtiter assay, 21:129–133

Yeasts
NCCLS standard broth macrodilution assay for, 21:129–133
and one-day vs. two-day incubation of urine cultures, 21:55–56
Wampole Isolater and, 23:1–9

Zymark robotic system, automated PCR performed by, 21:181–185